Nicole D. Urban

Research Professor Emeritus, Health Services


ScD   Harvard University, 1978   (Biostatistics, Health Services Admin)
MS   Harvard University, 1973   (Biostatistics)
BA   Simmons College, 1970   (English Literature)

Contact Info


Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N., MP900
Seattle, WA 98109-1024

campus box:   358080
voice:   206-667-6774
fax:   206-667-7850


Nicole Urban is a Member of the Cancer Prevention Research Program of the Public Health Sciences Division and Program Head of the Gynecologocal Cancer Research Program at the Fred Hutchinson Cancer Research Center. She is also the Scientific Director of the Marsha Rivkin Center for Ovarian Cancer Research. For the past 10 years Dr. Urban has studied ways to improve the use, performance and efficacy of breast and ovarian cancer screening tools. She is particularly interested in the evaluation of markers detectable in serum for use in cancer screening.

Breast/ovarian cancer screening; cost-effectiveness analysis

Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KA, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff DF. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst. 2015 Feb 16;107(4). pii: djv012. doi: 10.1093/jnci/djv012. Print 2015 Apr.  PMID: 25688116

Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, Urban N, Lubman DM. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. PLoS One. 2015 Mar 23;10(3):e0121112. doi: 10.1371/journal.pone.0121112. eCollection 2015.  PMID: 25799488    PMCID: PMC4370724

Richter M, Yumul R, Wang H, Saydaminova K, Ho M, May D, Baldessari A, Gough M, Drescher C, Urban N, Roffler S, Zubieta C, Carter D, Fender P, Lieber A. Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin. Mol Ther Methods Clin Dev. 2015 Mar 11;2:15005. doi: 10.1038/mtm.2015.5. eCollection 2015.  PMID: 26029716    PMCID: PMC4445001

Andersen MR, Thorpe J, Buist DS, Beatty JD, Watabayashi K, Hanson N, Resta R, Chubak J, Urban N. Cancer risk awareness and concern among women with a family history of breast or ovarian cancer. Behav Med. 2014 Jul 25:0. [Epub ahead of print]  PMID: 25062114    PMCID: PMC4469617

Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, Drapkin R, Urban N. Use of CA125 and HE4 Serum Markers to Predict Ovarian Cancer in Elevated-Risk Women. Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1383-93. doi: 10.1158/1055-9965.EPI-13-1361. Epub 2014 May 1.  PMID: 24789859    PMCID: PMC4082470